The Clorox Company (CLX) Down 4.7% — Should I Accept This Outcome and Sell?
The Clorox Company (CLX) endured a rough session this Monday, dropping $4.85 to close at $97.68 on the NYSE—its worst single-day decline in recent memory. The move pushed shares deeper into troubled territory, now sitting approximately 24.2% below the 52-week high of $128.90 reached on February 26, 2026. That gap is a sobering reminder of how much ground CLX has surrendered this year, and Monday's sell-off did nothing to suggest a floor has been found.
Trading volume told a particularly striking story. Nearly 13.4 million shares changed hands against a 90-day average of just 2.77 million—roughly five times the normal pace. That kind of volume surge on a down day is not easily dismissed; it signals broad, conviction-driven selling rather than routine profit-taking.
Why The Clorox Company Price is Moving Lower
Monday's decline reflects a market growing increasingly impatient with Clorox's deteriorating margin profile and a cautious outlook that offers little near-term relief. Shares fell from roughly $102 at the open to the high-$98s before closing near $97.68, down $4.27, or 4.16%, as of 3:58 p.m. ET a—a move driven not by a fresh earnings miss but by renewed analyst concern about weak underlying demand and severe margin pressure. The catalyst bringing that concern back to the surface was Clorox's fiscal 2027 guidance and the cost risks embedded in it, which left investors weighing whether the stock's dividend yield adequately compensates for the fundamental headwinds ahead.
The underlying numbers from the August 3 quarterly report explain the anxiety. While Clorox technically beat estimates—adjusted EPS of $1.66 versus the $1.64 consensus and revenue of $1.95 billion against a $1.91 billion expectation—the year-over-year comparisons were far less flattering. Revenue fell 2% from the prior year, adjusted EPS plunged 42% from $2.87, and gross margin collapsed 520 basis points to 41.3%. Management attributed the damage to lower volumes, GOJO acquisition costs, commodity inflation, and higher manufacturing and logistics expenses. Fiscal 2027 guidance projects adjusted EPS of $5.70–$6.00, but with inflation expected to exceed $200 million, the market is clearly skeptical that acquisition synergies and promised cost savings can keep pace with persistent margin erosion.
Analyst downgrades compounded the pressure. On August 4, HSBC slashed its price target to $104 from $129—a substantial reset that implies the firm sees limited upside even from current depressed levels. RBC joined in the same day, cutting its target to $110 from $118, and went a step further by arguing that reported fiscal 2027 sales growth could materially overstate underlying growth, which RBC estimated at only 0%–1%. That assessment cuts to the heart of what ails CLX right now: headline figures that look manageable at a glance mask a business where real organic momentum has nearly stalled.
What is the The Clorox Company Rating - Should I Sell?
Weiss Ratings assigns CLX a C- rating. Current recommendation is Hold.
That C- sits at the lower end of the Hold range—a meaningful distinction from a straightforward C, and one that reflects genuine tension between the pockets of strength in Clorox's financials and the real vulnerabilities that have become harder to ignore. The standout number is ROE of 163.76%, which earns the Excellent Efficiency Index—an extraordinary figure that reflects Clorox's ability to extract returns from its equity base, though it is heavily influenced by the company's leveraged capital structure rather than purely operational outperformance. Profit margin of 8.73% is modest but functional for a household products manufacturer operating in a cost-intensive environment, contributing to an overall picture that is not without merit.
The trouble shows up in the growth and risk indicators. Revenue growth of -2.01% lands the Fair Growth Index, a figure that aligns uncomfortably well with RBC's estimate of 0%–1% underlying organic growth—suggesting the top-line story is stagnating rather than recovering. The Fair Solvency Index warrants attention given the company's debt load and the ongoing financial demands of the GOJO acquisition, which continues to weigh on cash flows. Most concerning for performance-oriented investors is the Weak Total Return Index paired with a Weak Volatility Index, a combination that captures both the stock's recent underperformance and its tendency for uncomfortable price swings—as Monday's session vividly illustrated.
Within the Consumer Staples sector, Clorox trails several peers. Colgate-Palmolive Company (CL, C+) and Church & Dwight Co., Inc. (CHD, C+) both carry stronger ratings, reflecting more stable margin profiles and less acquisition-related uncertainty. The Procter & Gamble Company (PG, C), Kenvue Inc. (KVUE, C), and Kimberly-Clark Corporation (KMB, C) each hold a plain C—still a step above CLX's C- in Weiss's framework. That relative positioning places Clorox at the bottom of its peer group by Weiss's assessment, a ranking consistent with the operational challenges the company is currently navigating.
About The Clorox Company
The Clorox Company (CLX) is a Consumer Staples company best known for its portfolio of cleaning, disinfecting, and lifestyle brands sold to households, businesses, and institutions across the United States and in select international markets. Its flagship bleach and cleaning products remain deeply embedded in everyday consumer routines, supported by decades of brand recognition and distribution reach that spans mass retail, grocery, and e-commerce channels. The company's brand strength in core categories has historically afforded it a degree of pricing power that commodity-focused competitors cannot easily match.
Beyond its cleaning and disinfecting heritage, Clorox operates across a diversified set of consumer categories through well-recognized brand names in food products, water filtration, natural personal care, and cat litter. The recent acquisition of GOJO Industries—maker of Purell hand sanitizer—expands its footprint into professional-grade hygiene, broadening the company's exposure to institutional and healthcare end markets. That diversification is strategically sensible over the long term, though it has introduced meaningful integration costs and debt that are currently pressuring margins and free cash flow.
Clorox's competitive advantages rest on brand loyalty, retail shelf presence, and proprietary formulations that support consumer trust in product efficacy. Its supply chain and manufacturing capabilities, built around high-volume production of commodity-adjacent goods, require ongoing investment to maintain efficiency as input costs fluctuate. The combination of a large installed consumer base, extensive distribution infrastructure, and a growing professional hygiene platform gives Clorox a defensible market position—even as it works through a challenging cost environment.
Investor Outlook
The Clorox Company (CLX) carries a Weiss Rating of C- (Hold), and the near-term path forward depends heavily on whether management can demonstrate credible margin recovery while absorbing more than $200 million in expected inflation costs in fiscal 2027. Investors will want to watch gross margin trends closely in upcoming quarters, along with any updated commentary on GOJO integration progress and the pace of cost savings. The 4.85% dividend yield offers some income cushion, but the Weak Total Return Index and Weak Volatility Index signal that the ride is unlikely to be smooth. See full rankings of all C--rated Consumer Staples stocks inside the Weiss Stock Screener.
--